Cargando…

Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report

BACKGROUND: Antisynthetase syndrome is a rare and debilitating multiorgan disease characterized by inflammatory myopathy, interstitial lung disease, cutaneous involvement, and frequent chronic inflammation of the joints. Standard treatments include corticosteroids and immunosuppressants. In some cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cherin, Patrick, de Jaeger, Christophe, Crave, Jean-Charles, Delain, Jean-Christophe, Tadmouri, Abir, Amoura, Zahir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336681/ https://www.ncbi.nlm.nih.gov/pubmed/28257650 http://dx.doi.org/10.1186/s13256-017-1211-9

Ejemplares similares

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
por: Patrick, Cherin, et al.
Publicado: (2014)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015)

Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
por: Cherin, Patrick, et al.
Publicado: (2015)

In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis: An Overlapping Rheumatoid Arthritis and Antisynthetase Syndrome
por: Meyer, Alain, et al.
Publicado: (2015)

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”
por: Bienvenu, B., et al.
Publicado: (2016)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome
por: Marie, Isabelle, et al.
Publicado: (2013)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
por: Rosenbach, Kevin, et al.
Publicado: (2023)

Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study
por: Chérin, Patrick, et al.
Publicado: (2020)

Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes
por: Dieval, Céline, et al.
Publicado: (2015)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Contribution of Flexig mobile application to assess adherence of patients treated with immunoglobulins in chronic diseases
por: Pindi Sala, Taylor, et al.
Publicado: (2023)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Acute Respiratory Failure as the First Manifestation of Antisynthetase Syndrome
por: Toujani, Sonia, et al.
Publicado: (2017)

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
por: Pollock, Richard F, et al.
Publicado: (2018)

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
por: Dimou, Maria, et al.
Publicado: (2023)

Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome
por: Mori, Izumi, et al.
Publicado: (2008)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course
por: Cavagna, Lorenzo, et al.
Publicado: (2019)

Intravenous immunoglobulin treatment stabilizing a patient with Anti-PL7 antisynthetase syndrome with interstitial lung disease and eosinophilic inflammation
por: Peshbahar, Soran, et al.
Publicado: (2022)

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

A case of antisynthetase syndrome
por: Mavragani, Clio P., et al.
Publicado: (2020)

Antisynthetase Syndrome With Paraneoplastic Antibodies
por: Pokharel, Ashbina, et al.
Publicado: (2023)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H, et al.
Publicado: (2022)

Immune Globulin Subcutaneous (Human) 20%: In Primary Immunodeficiency Disorders
por: McCormack, Paul L.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6g9ubaf8qfjkop64hrb2m3qogs